The development of safe and reliable haematopoietic cell transplantation (HCT) protocols to treat human patients with malignant and non‐malignant blood disorders was highly influenced by preclinical studies obtained in random‐bred canines. The surmounted barriers included recognizing the crucial importance of histocompatibility matching, establishing long‐term donor haematopoietic cell engraftment, preventing graft‐vs‐host disease and advancing effective conditioning and post‐grafting immunosuppression protocols, all of which were evaluated in canines. Recent studies have applied the tolerance inducing potential of HCT to solid organ and vascularized composite tissue transplantation. Several advances in HCT and tolerance induction that were first developed in the canine preclinical model and subsequently applied to human patients are now being recruited into veterinary practice for the treatment of malignant and non‐malignant disorders in companion dogs. Here, we review recent HCT advancements attained in the canine model during the past 15 years.

中文翻译：

---

犬造血细胞移植临床前模型的发展和转化相关性。

用于治疗患有恶性和非恶性血液疾病的人类患者的安全可靠的造血细胞移植 (HCT) 方案的开发受到在随机繁殖犬科动物中获得的临床前研究的高度影响。克服的障碍包括认识到组织相容性匹配的至关重要性、建立长期供体造血细胞移植、预防移植物抗宿主病以及推进有效的调节和移植后免疫抑制方案，所有这些都在犬科动物中进行了评估。最近的研究已将 HCT 的耐受诱导潜力应用于实体器官和血管化复合组织移植。HCT 和耐受诱导方面的几项进展首先在犬临床前模型中开发并随后应用于人类患者，现在正被招募到兽医实践中，用于治疗伴侣犬的恶性和非恶性疾病。在这里，我们回顾了过去 15 年来在犬类模型中取得的 HCT 最新进展。